William Blair & Company
LENZ

William Blair & Company’s LENZ Therapeutics LENZ Stock Holding History

William Blair & Company’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,207
Closed -$163K – 2012
2025
Q4 		$163K Buy
10,207
+2,215
+28% +$64.6K ﹤0.01% 1501
2025
Q3 		$372K Buy
+7,992
New +$294K ﹤0.01% 1224

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

William Blair & Company's LENZ Position: Q1 2026 in Review

William Blair & Company sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 10,207 shares — an estimated $163K sold.

William Blair & Company first reported a position in LENZ in Q3 2025 and held it in 2 quarters. The position peaked at $372K in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • William Blair & Company reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • William Blair & Company sold 10,207 LENZ Therapeutics shares in Q1 2026, an estimated $163K.
  • William Blair & Company first reported a position in LENZ Therapeutics in Q3 2025 and held it in 2 quarters.
  • William Blair & Company's LENZ Therapeutics position peaked at $372K in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.